✦ LIBER ✦

Cabazitaxel (CBZ) in metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (Doc): Single CUP center results

✍ Scribed by Ntokou, A.; Zylis⁎, D.; Markos, L.; Kaltsas, S.; Stamatopoulou, S.; Pouliou, E.; Agrogianni, N.; Florou, K.; Gkeka, D.; Stavrinidis, H.; Ardavanis, A.

Book ID: 122464725
Publisher: Elsevier
Year: 2012
Tongue: English
Weight: 68 KB
Volume: 3
Category: Article
ISSN: 1879-4068
DOI: 10.1016/j.jgo.2012.10.108

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cabazitaxel for Patients with Metastatic

Cabazitaxel for Patients with Metastatic Castrate-resistant Prostate Cancer Previously Treated with a Docetaxel-containing Regimen: A Single Cancer Centre Experience using UK Early Access Programme and Cancer Drugs Fund

✍ Kelly, C.; Cornthwaite, S.; Birtle, A. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 45 KB

128 Cabazitaxel plus prednisone for pati

128 Cabazitaxel plus prednisone for patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing regimen: Interim analysis on treatment associated side effects resulting from a compassionate-use programme (CUP)

✍ A. Heidenreich; P. Albers; C. Bokemeyer; P. Goebell; J. Gschwend; K. Miller; S M 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 37 KB

7044 POSTER Cabazitaxel Plus Prednisone

7044 POSTER Cabazitaxel Plus Prednisone for Patients With Metastatic Castration-resistant Prostate Cancer Previously Treated With a Docetaxel-containing Regimen – Interim Analysis Results From an Ongoing Compassionate-use Programme

✍ Heidenreich, A.; Scholz, H.J.; van Oort, I.; Bavbek, S.; Mueller, S.; Ozguroglu, 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 43 KB

104 Overall survival with cabazitaxel is

104 Overall survival with cabazitaxel is strongly related to PSA response: Results of a retrospective registry in metastatic castration resistant prostate cancer (mCRPC)

✍ Angelergues, A.; Mercier, F.; Flechon, A.; Guillot, A.; Le Moulec, S.; Gravis, G 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 123 KB

106 Cabazitaxel adverse events are manag

106 Cabazitaxel adverse events are manageable in senior adults with metastatic castration-resistant prostate cancer (mCRPC): Results of the European Compassionate Use Programme

✍ Heidenreich, A.; Bracarda, S.; Mason, M.; Ozen, H.; Sengelov, L.; Gerritsen, W.; 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 102 KB

1090 CLINICAL BENEFIT OF CABAZITAXEL PLU

1090 CLINICAL BENEFIT OF CABAZITAXEL PLUS PREDNISONE IN THE TROPIC TRIAL IN MEN WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC) WHO PROGRESSED AFTER DOCETAXEL-BASED TREATMENT

✍ Tombal, B.; Oudard, S.; Ozguroglu, M.; Hansen, S.; Kocak, I.; Gravis, G.; Sartor 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 262 KB